<DOC>
	<DOCNO>NCT00613691</DOCNO>
	<brief_summary>This 2-part , open-label , single-arm , dose escalation study . Part I define Maximum Tolerated Dose ( MTD ) optimal dose SPI-1620 evaluate PK PD property . Once MTD SPI-1620 identify , second phase study focus dose escalation docetaxel study group 3-6 patient . This part study ass safety tolerability increase dos docetaxel administer optimal dose SPI 1620 define Part I .</brief_summary>
	<brief_title>A Phase I , Open-label , Ascending Dose Study Safety , Tolerability , Pharmacokinetics Pharmacodynamics Endothelin B Agonist , SPI-1620 , Patients With Recurrent Progressive Carcinoma</brief_title>
	<detailed_description>This 2-part , open-label , single-arm , dose escalation study . Part I define Maximum Tolerated Dose ( MTD ) optimal dose SPI-1620 evaluate PK PD property . Eligible patient receive SPI-1620 deliver intravenously one minute Days 1 , 8 15 . On Day 8 patient undergo series four H215O PET Blood Flow ( BF ) scan use assess alteration BF induce SPI-1620 tumor non-tumor ROIs ( Region Interest ) . Fifteen minute receive SPI-1620 Day 15 , patient receive docetaxel , 60 mg/m2 , administer infusion 1 hour . Accelerated dose escalation SPI-1620 employ : one patient treat dose level 100 % increase dose level . If grade 2 high , related AE occurs , trial revert 3-patient cohort 40 % dose escalation group . There intrapatient dose escalation . Dose escalation continue either increase tumor blood flow assess H215O PET scan , significant toxicity observe . Once MTD SPI-1620 identify , second phase study focus dose escalation docetaxel study group 3-6 patient . This part study ass safety tolerability increase dos docetaxel administer optimal dose SPI 1620 define Part I . If 60 mg/m 2 tolerated Part I six patient Part II receive docetaxel dose 80 mg/m2 every 3 week . If tolerate next group patient receive docetaxel 100 mg/m2 every 3 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>All following inclusion criterion must meet prior participation study 1 . The patient must sign informed consent . A signed consent form require prior performance protocolrelated procedure assessment . 2 . The patient must &gt; = 18 year age . 3 . The patient must progressive recurrent carcinoma fail standard therapy his/her tumor . 4 . The patient must negative CT scan contrast brain MRI brain within 45 day enrollment . 5 . The patient must use acceptable/effective method contraception female patient childbearing potential . 6 . The patient must negative serum pregnancy test within 14 day enter protocol female childbearing potential . 7 . The patient must ECOG score &lt; = 2 . 8 . The patient must willing able abide protocol . None exclusion criterion may meet prior patient participation study 1 . The patient history CHF , migraine , coagulopathy , stroke inadequately control hypertension . 2 . The patient asthma symptomatic COPD . 3 . The patient autonomic nerve dysregulation syndrome . 4 . The patient angina take nitrate MI within past six month . 5 . The patient significant ventricular arrhythmia , class III IV CHF know coronary stenosis &gt; 80 % undergone either angioplasty CABG 6 . The patient take phosphodiesterase inhibitor 7 . The patient malignant poorly control hypertension ( &gt; 160/100 ) 8 . The patient symptomatic orthostatic hypotension 9 . The patient take arterial vasodilator nifedipine amlodipine alpha blocker terazosin , tamsulosin prazosin . 10 . The patient screen absolute neutrophil count le 1.5 K/uL 11 . The patient screen platelet count le 100 K/uL . 12 . The patient screen creatinine great 2.0 mg/dL 13 . The patient screen amino alanine transferase ( ALT ) , aspartate aminotransferase ( AST ) &gt; 2.5 time upper limit laboratory reference range total bilirubin &gt; 1.0 mg/dL . 14 . The patient know immunodeficiency disorder . 15 . The patient enrol , patient plan enroll , concurrent study another investigational product . 16 . The patient taking , patient plan take cancer treatment study except patient prostate cancer use LHRH agonist therapy . 17 . The patient know hypersensitivity component SPI 1620 docetaxel . 18 . The patient previously fail treatment docetaxel his/her tumor dose SPI1620 show enhance tumor blood flow identify . 19 . The patient tumor least 1cm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Refractory</keyword>
	<keyword>Progressive</keyword>
</DOC>